MCID: HPT004
MIFTS: 45

Hepatic Coma

Categories: Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Coma

MalaCards integrated aliases for Hepatic Coma:

Name: Hepatic Coma 12 54 15 71
Hepatic Encephalopathy 43 71
Hepatocerebral Intoxication 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12550
MeSH 43 D006501
SNOMED-CT 67 72836002
ICD10 32 K72.91
UMLS 71 C0019147 C0019151

Summaries for Hepatic Coma

MalaCards based summary : Hepatic Coma, also known as hepatic encephalopathy, is related to viral hepatitis and acute liver failure. An important gene associated with Hepatic Coma is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Metformin and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Hepatic Coma

Diseases related to Hepatic Coma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 32.8 GPT F2 ALB AFP
2 acute liver failure 30.6 TSPO GPT F2 ALB
3 hepatitis a 30.5 GPT F3 F2 ALB AFP
4 acute cystitis 30.4 GPT F2 ALB
5 infantile liver failure syndrome 1 30.3 GPT F2 ALB
6 portal vein thrombosis 30.2 SERPINC1 F2 AFP
7 hepatic encephalopathy 30.2 TSPO GPT F2 ALB AFP
8 acute kidney failure 30.2 GPT F2 ALB
9 non-a-e hepatitis 30.1 F2 ALB
10 schistosomiasis 30.0 GPT F2 ALB
11 peliosis hepatis 30.0 GPT AFP
12 wilson disease 30.0 GPT F2 ALB
13 autoimmune hepatitis 30.0 GPT F2 ALB
14 hepatorenal syndrome 30.0 GPT F2 ALB AFP
15 hepatitis e 29.9 GPT F2 ALB
16 cholestasis 29.8 GPT F2 ALB
17 non-alcoholic steatohepatitis 29.8 GPT ALB ACACA
18 alcoholic hepatitis 29.8 GPT F2 ALB
19 cholecystitis 29.7 GPT F2 ALB
20 kwashiorkor 29.7 GPT F2 ALB
21 eclampsia 29.7 SERPINC1 F2 ALB
22 biliary atresia 29.7 GPT F2 ALB
23 metabolic acidosis 29.6 GPT F2 ALB
24 active peptic ulcer disease 29.6 F3 F2 ALB
25 hepatitis b 29.6 GPT F2 ALB AFP
26 inherited metabolic disorder 29.5 GPT F2 ALB
27 portal hypertension 29.5 GPT F3 F2 ALB
28 liver disease 29.5 GPT F3 F2 ALB AFP
29 budd-chiari syndrome 29.5 SERPINC1 F3 F2
30 intracranial hypertension 29.4 SERPINC1 F3 F2 ALB
31 rocky mountain spotted fever 29.3 GPT F3
32 hypothyroidism 29.2 GPT F3 F2 ALB
33 liver cirrhosis 29.1 SERPINC1 GPT F3 F2 ALB AFP
34 papilledema 29.1 SERPINC1 F3 F2
35 alcoholic liver cirrhosis 29.1 GPT F2 ALB AHSG AFP
36 hypersplenism 29.0 SERPINC1 GPT F2 ALB
37 cholangitis 29.0 GPT F3 F2 ALB
38 carotid artery thrombosis 29.0 SERPINC1 F3
39 fatty liver disease 29.0 GPT ALB AHSG ACACA
40 respiratory failure 28.9 GPT F3 F2 ALB
41 thrombophilia due to thrombin defect 28.9 SERPINC1 F3 F2
42 antiphospholipid syndrome 28.8 SERPINC1 F3 F2
43 aspiration pneumonia 28.8 GPT F3 F2 ALB
44 exanthem 28.8 GPT F3 F2 ALB
45 pulmonary hypertension 28.8 SERPINC1 F3 F2 ALB
46 bilirubin metabolic disorder 28.7 GPT F3 F2 ALB AFP
47 disseminated intravascular coagulation 28.6 SERPINC1 GPT F3 F2
48 esophageal varix 28.4 SERPINC1 GPT F3 F2 ALB AFP
49 thrombocytopenia 28.4 SERPINC1 GPT F3 F2 ALB
50 stroke, ischemic 28.4 TSPO SERPINC1 F3 F2 ALB

Graphical network of the top 20 diseases related to Hepatic Coma:



Diseases related to Hepatic Coma

Symptoms & Phenotypes for Hepatic Coma

MGI Mouse Phenotypes related to Hepatic Coma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 ACACA AFP AHSG ALB DBI F2
2 cardiovascular system MP:0005385 9.86 ALB F2 F3 GOT1 HRH3 SCN1A
3 liver/biliary system MP:0005370 9.43 ACACA AFP ALB DBI SERPINC1 TSPO
4 mortality/aging MP:0010768 9.32 ACACA AFP ALB DBI F2 F3

Drugs & Therapeutics for Hepatic Coma

Drugs for Hepatic Coma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
5
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
9
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Vancomycin Approved Phase 4 1404-90-6 14969 441141
12
Cefoxitin Approved Phase 4 35607-66-0 441199
13
Azithromycin Approved Phase 4 83905-01-5 447043 55185
14
Insulin aspart Approved Phase 4 116094-23-6 16132418
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
19
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
20
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
21
Promethazine Approved, Investigational Phase 4 60-87-7 4927
22
Histamine Approved, Investigational Phase 4 51-45-6 774
23
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
24
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
25
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
26
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
27
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
28
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
29
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
30
Azathioprine Approved Phase 4 446-86-6 2265
31
Lactulose Approved Phase 4 4618-18-2 11333
32
Norepinephrine Approved Phase 4 51-41-2 439260
33
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
34
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
35
Atorvastatin Approved Phase 4 134523-00-5 60823
36
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
37
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
38
Tolvaptan Approved Phase 4 150683-30-0 216237
39
Ethanol Approved Phase 4 64-17-5 702
40
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
41
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
42
Lorazepam Approved Phase 4 846-49-1 3958
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
44
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
45
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
46 Hypoglycemic Agents Phase 4
47 GABA Modulators Phase 4
48 Anti-Anxiety Agents Phase 4
49 Anesthetics, General Phase 4
50 Psychotropic Drugs Phase 4

Interventional clinical trials:

(show top 50) (show all 338)
# Name Status NCT ID Phase Drugs
1 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study Unknown status NCT03077217 Phase 4 Rifaximin
2 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
3 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
4 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
5 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
6 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
7 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
8 Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Unknown status NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
9 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
10 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
11 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
12 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
13 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
14 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
15 Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Completed NCT01559519 Phase 4 Albumin
16 High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
17 Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study Completed NCT00955500 Phase 4
18 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
19 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
20 A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Lactulose
21 The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
22 Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
23 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
24 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
25 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
26 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
27 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
28 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
29 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
30 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
31 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
32 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
33 Study of the Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4
34 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
35 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
36 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
37 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
39 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
40 Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) Recruiting NCT04436601 Phase 4 Polyethylene Glycols;Lactulose
41 Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. Recruiting NCT04073290 Phase 4 Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution
42 Use of HA 330-II for Hemofiltration in Patients With Acute Liver Failure as a Bridge to Liver Transplantation: Clinical Evaluation Protocol. Recruiting NCT04243655 Phase 4 Standard medical treatment (SMT)
43 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
44 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
45 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
46 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
47 Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology Terminated NCT01824589 Phase 4
48 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
49 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
50 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos

Search NIH Clinical Center for Hepatic Coma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Kanamycin Sulfate
Lactulose
NEOMYCIN SO4 PWDR

Cochrane evidence based reviews: hepatic encephalopathy

Genetic Tests for Hepatic Coma

Anatomical Context for Hepatic Coma

MalaCards organs/tissues related to Hepatic Coma:

40
Liver, Brain, Testes, Cortex, Colon, Kidney, Cerebellum

Publications for Hepatic Coma

Articles related to Hepatic Coma:

(show top 50) (show all 9255)
# Title Authors PMID Year
1
Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. 61 54
16563564 2006
2
The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. 61 54
12020611 2002
3
Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. 54 61
11929388 2002
4
Acute liver failure. 61 54
11132456 1999
5
The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study. 54 61
9347201 1997
6
[Severe Amanita phalloides poisoning in a 7-year-old girl]. 61 54
8348662 1993
7
"Peripheral-type" (mitochondrial) benzodiazepine receptors in hepatic encephalopathy. 54 61
7748297 1993
8
Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. 61 54
1530786 1992
9
Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. 54 61
2161396 1990
10
Outcome of non-surgical dietary treatment with or without lactulose in dogs with congenital portosystemic shunts. 61
32194008 2020
11
Endothelin-1 level as a predictor of hepatopulmonary syndrome in liver cirrhosis. 61
32567294 2020
12
Causes and Rates of 30-Day Readmissions After Transjugular Intrahepatic Portosystemic Shunts. 61
32374665 2020
13
Effect of phosphatidylserine on cirrhosis-induced hepatic encephalopathy: Response to acute endotoxemia in cirrhotic rats. 61
32320707 2020
14
Acute Liver Injury and Decompensated Cirrhosis. 61
32505258 2020
15
Reply to comment: "Hospital readmission of patients with hepatic encephalopathy: Is the introduction of the formal caregiver useful in care management?" 61
32291168 2020
16
SIRT1 activation by resveratrol reverses atrophy of apical dendrites of hippocampal CA1 pyramidal neurons and neurobehavioral impairments in moderate grade hepatic encephalopathy rats. 61
32334029 2020
17
Validation of Knowledge Questionnaire for Patients With Liver Cirrhosis. 61
31809918 2020
18
Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. 61
32452561 2020
19
Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNK/caspase-8/TRAIL activation in rats. 61
32259601 2020
20
Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. 61
32227294 2020
21
Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. 61
32181561 2020
22
L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism. 61
32424601 2020
23
Detection of High-Level Rifaximin Resistance in Enteric Bacteria by Agar Screen. 61
31855490 2020
24
Clinical management of type C hepatic encephalopathy. 61
32213035 2020
25
Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy. 61
32463782 2020
26
Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. 61
32568474 2020
27
Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt. 61
32541240 2020
28
Hepatic encephalopathy due to a congenital portosystemic shunt: a disease with a changeable presentation. 61
32496112 2020
29
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. 61
31954206 2020
30
Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy. 61
32495311 2020
31
The autophagic marker p62 highlights Alzheimer type II astrocytes in metabolic/hepatic encephalopathy. 61
32483828 2020
32
Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration. 61
32048037 2020
33
Combined Scores from the EncephalApp Stroop Test, Number Connection Test B, and Serial Dotting Test Accurately Identify Patients With Covert Hepatic Encephalopathy. 61
31712074 2020
34
Propofol alone prevents worsening hepatic encephalopathy rather than midazolam alone or combined sedation after esophagogastroduodenoscopy in compensated or decompensated cirrhotic patients. 61
32433420 2020
35
Outcomes of lactulose plus branched-chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. 61
31943593 2020
36
Minimal Hepatic Encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes. 61
32572109 2020
37
A novel method: can stapedial acoustic reflex have a role in the diagnosis of minimal hepatic encephalopathy? 61
32568804 2020
38
A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in Cirrhotic Patients. 61
32523059 2020
39
Spastic paraparesis associated with advanced liver cirrhosis: a condition obscure in terms of treatment and prognosis. 61
32513765 2020
40
Low health literacy is associated with frailty and reduced likelihood of liver transplant listing: a prospective cohort study. 61
32567232 2020
41
Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection. 61
32500937 2020
42
Weekend admissions with ascites are associated with delayed paracentesis: A nationwide analysis of the 'weekend effect'. 61
32540327 2020
43
Acute Liver Failure Caused by Use of Fat Burner: A Case Report. 61
32192741 2020
44
Effect of opioid treatment on clinical outcomes among cirrhotic patients in the United States. 61
32096883 2020
45
Extracorporeal renal and liver support in pediatric acute liver failure. 61
32500250 2020
46
Metabolomic signature as a predictor of liver disease events in patients with HIV/HCV co-infection. 61
32502252 2020
47
Admission Characteristics Identify Risk of Pediatric Acute-on Liver Failure. 61
32443031 2020
48
Liver Cirrhosis Complications Management At The Emergency Department. 61
32493202 2020
49
Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis. 61
31834050 2020
50
Calprotectin as Diagnostic Marker for Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Cirrhosis. 61
32538038 2020

Variations for Hepatic Coma

Expression for Hepatic Coma

Search GEO for disease gene expression data for Hepatic Coma.

Pathways for Hepatic Coma

GO Terms for Hepatic Coma

Cellular components related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 SERPINC1 GPT F3 F2 ALB AHSG
2 extracellular exosome GO:0070062 9.76 TSPO SERPINC1 GPT GOT1 F2 DBI
3 collagen-containing extracellular matrix GO:0062023 9.62 SERPINC1 F3 F2 AHSG
4 blood microparticle GO:0072562 9.26 SERPINC1 F2 ALB AHSG
5 endoplasmic reticulum lumen GO:0005788 9.1 SERPINC1 F2 DBI ALB AHSG AFP

Biological processes related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.56 SERPINC1 ALB AHSG AFP
2 regulation of blood coagulation GO:0030193 9.16 SERPINC1 F2
3 hemostasis GO:0007599 9.13 SERPINC1 F3 F2
4 cellular protein metabolic process GO:0044267 9.02 SERPINC1 F2 ALB AHSG AFP

Molecular functions related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transaminase activity GO:0008483 8.96 GPT GOT1
2 pyridoxal phosphate binding GO:0030170 8.8 GPT GOT1 ALB

Sources for Hepatic Coma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....